Search Results
Found 2 results
510(k) Data Aggregation
(7 days)
PNI
The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is for the semi-quantitative determination of autoantibodies to Aquaporin-4 in human serum. The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay may be useful as an aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is not to be used in conjunction with other clinical, laboratory, and radiological (e.g. MRI) findings.
Not Found
This is a 510(k) premarket notification for an in vitro diagnostic (IVD) device, not an AI/ML medical device. Therefore, many of the requested categories for AI/ML device studies are not applicable.
Here's an attempt to answer the questions based on the provided text, primarily focusing on the device itself and applicable sections:
-
A table of acceptance criteria and the reported device performance
The provided text is a letter from the FDA acknowledging the substantial equivalence of the device and contains the Indications for Use. It does not include specific acceptance criteria or performance data tables. For IVD devices, such data would typically be found in the 510(k) summary or the full submission, which is not part of this document. -
Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
This information is not provided in the supplied FDA letter or Indications for Use statement. -
Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)
This information is not applicable and not provided. The device is an ELISA assay for autoantibodies, and ground truth for such assays would typically be established by clinical diagnosis and/or correlation with other lab tests, not by expert interpretation of images/data in the same way as an imaging AI device. -
Adjudication method (e.g., 2+1, 3+1, none) for the test set
This information is not applicable and not provided. -
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not applicable. The device is an IVD ELISA assay, not an AI-assisted diagnostic tool that humans would use to interpret cases. -
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This information is not applicable. The device is a laboratory assay. Its performance is evaluated intrinsically through analytical and clinical studies, not typically as an "algorithm only" or "human-in-the-loop" system in the context of AI. -
The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The device is an assay for autoantibodies to Aquaporin-4 (AQP4Ab) to aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The "ground truth" for evaluating such a diagnostic aid would typically be the definitive clinical diagnosis of NMO/NMOSD based on established diagnostic criteria, which may involve a combination of clinical presentation, neurological examination, imaging (e.g., MRI findings), and other laboratory tests. The device itself is designed to contribute to this diagnosis. -
The sample size for the training set
This information is not provided in the supplied FDA letter or Indications for Use statement. For an IVD assay development, a "training set" might refer to samples used for assay optimization and cutoff determination, but specific details are not given here. -
How the ground truth for the training set was established
This information is not provided. Similar to the test set, any "training set" for an IVD assay would likely use confirmed clinical diagnoses for NMO/NMOSD as the ground truth.
Ask a specific question about this device
(298 days)
PNI
The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is for the semiquantitative determination of autoantibodies to Aquaporin-4 in human serum. The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay may be useful as an aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is not to be used alone and is to be used in conjunction with other clinical, laboratory, and radiological (e.g., MRI) findings.
The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay consists of ELISA strip wells coated with human recombinant AQP4 protein (amino acid position: 23-323) (96 wells in total) and supplied as 12 strips of 8 wells in a frame and sealed in a foil pouch with desiccant; ready-to-use 5 levels of calibrators (1.5, 5, 20, 40, and 80 U/mL), 5 x 0.7 mL; a ready-to-use positive (2 x . 7 mL) and a negative control serum (1 x 0.7 mL); AQP4-Biotin (lyophilized), 3 x 1.5 mL (reconstituted); ready-to-use reconstitution buffer for AQP4-Biotin, 1 x 10 mL; Streptavidin Peroxidase (SA-POD dilute before use) 1 x 0.8 mL; ready-to-use diluent for SA-POD, 1 x 15 mL; ready-to-use peroxidase substrate (TMB), 1 x 15 mL; concentrated wash solution (dilute 1:10 with deionized water before use), 1 x 120 mL and ready-to-use stop solution, 1 x 14 mL.
KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay: Acceptance Criteria and Performance Study
This document summarizes the acceptance criteria and the study demonstrating the KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay meets these criteria, based on the provided text.
1. Table of Acceptance Criteria and Reported Device Performance
The provided text focuses on the performance characteristics of the KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay. While explicit "acceptance criteria" are not always presented as a direct numerical threshold in this document, the studies demonstrate that the device's performance metrics were "within the manufacturer's pre-determined acceptance limit" or "deemed appropriate" based on the established cut-off. The table below compiles the reported performance metrics.
Performance Characteristic | Acceptance Criteria (Implied/Stated) | Reported Device Performance |
---|---|---|
Precision | Within manufacturer's pre-determined acceptance limit for %CV | All %CV values within limit. Example Total %CVs: 6.7% - 15.0% |
Reproducibility (Site-to-site) | R² > 0.99 for correlation between sites | R² > 0.99 for all comparisons (Lab 1 vs. Lab 2, Lab 1 vs. Lab 3, Lab 2 vs. Lab 3) |
Reproducibility (Lot-to-lot) | %CV for all samples within a specified range | %CV values ranged from 3.22% - 14.13% |
Linearity Range | Within manufacturer's pre-determined acceptance criteria for recovery | Linear from 1.5 - 79.5 U/mL. Recovery: 80.76% - 118.38% |
Hook Effect | No hook effect observed up to a certain concentration | No hook effect observed up to 14000 U/mL |
Limit of Blank (LoB) | Not explicitly stated; determined by testing negative samples |
Ask a specific question about this device
Page 1 of 1